FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:AAK1-RFWD2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: AAK1-RFWD2
FusionPDB ID: 67
FusionGDB2.0 ID: 67
HgeneTgene
Gene symbol

AAK1

RFWD2

Gene ID

112268437

64326

Gene nameuncharacterized protein FLJ45252COP1 E3 ubiquitin ligase
SynonymsAAK1CFAP78|FAP78|RFWD2|RNF200
Cytomap

-

1q25.1-q25.2

Type of geneprotein-codingprotein-coding
Descriptionuncharacterized protein FLJ45252alternative protein AAK1E3 ubiquitin-protein ligase COP1E3 ubiquitin-protein ligase RFWD2RING finger protein 200RING-type E3 ubiquitin transferase RFWD2constitutive photomorphogenesis protein 1 homologconstitutive photomorphogenic protein 1putative ubiquitin ligase COP1ri
Modification date2020030320200313
UniProtAcc

Q2M2I8

Main function of 5'-partner protein: FUNCTION: Regulates clathrin-mediated endocytosis by phosphorylating the AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) which ensures high affinity binding of AP-2 to cargo membrane proteins during the initial stages of endocytosis (PubMed:17494869, PubMed:11877457, PubMed:11877461, PubMed:12952931, PubMed:14617351, PubMed:25653444). Isoform 1 and isoform 2 display similar levels of kinase activity towards AP2M1 (PubMed:17494869). Preferentially, may phosphorylate substrates on threonine residues (PubMed:11877457, PubMed:18657069). Regulates phosphorylation of other AP-2 subunits as well as AP-2 localization and AP-2-mediated internalization of ligand complexes (PubMed:12952931). Phosphorylates NUMB and regulates its cellular localization, promoting NUMB localization to endosomes (PubMed:18657069). Binds to and stabilizes the activated form of NOTCH1, increases its localization in endosomes and regulates its transcriptional activity (PubMed:21464124). {ECO:0000269|PubMed:11877457, ECO:0000269|PubMed:11877461, ECO:0000269|PubMed:12952931, ECO:0000269|PubMed:14617351, ECO:0000269|PubMed:17494869, ECO:0000269|PubMed:18657069, ECO:0000269|PubMed:21464124, ECO:0000269|PubMed:25653444}.; FUNCTION: (Microbial infection) By regulating clathrin-mediated endocytosis, AAK1 plays a role in the entry of hepatitis C virus as well as for the lifecycle of other viruses such as Ebola and Dengue. {ECO:0000269|PubMed:25653444, ECO:0000305|PubMed:31136173}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000406297, ENST00000409068, 
ENST00000409085, ENST00000470281, 
ENST00000308769, ENST00000367669, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score19 X 13 X 11=271728 X 17 X 12=5712
# samples 2227
** MAII scorelog2(22/2717*10)=-3.62643913669732
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(27/5712*10)=-4.40296466697827
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: AAK1 [Title/Abstract] AND RFWD2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: AAK1 [Title/Abstract] AND RFWD2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)AAK1(69870009)-RFWD2(175996824), # samples:1
Anticipated loss of major functional domain due to fusion event.AAK1-RFWD2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AAK1-RFWD2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AAK1-RFWD2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
AAK1-RFWD2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneRFWD2

GO:0010212

response to ionizing radiation

19805145



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:69870009/chr1:175996824)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across AAK1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across RFWD2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000409068AAK1chr269870009-ENST00000367669RFWD2chr1175996824-13834772151060281
ENST00000409068AAK1chr269870009-ENST00000308769RFWD2chr1175996824-10614772151060282
ENST00000409085AAK1chr269870009-ENST00000367669RFWD2chr1175996824-14465402781123281
ENST00000409085AAK1chr269870009-ENST00000308769RFWD2chr1175996824-11245402781123282
ENST00000406297AAK1chr269870009-ENST00000367669RFWD2chr1175996824-14465402781123281
ENST00000406297AAK1chr269870009-ENST00000308769RFWD2chr1175996824-11245402781123282

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000409068ENST00000367669AAK1chr269870009-RFWD2chr1175996824-0.0015236750.9984763
ENST00000409068ENST00000308769AAK1chr269870009-RFWD2chr1175996824-0.0023277310.99767226
ENST00000409085ENST00000367669AAK1chr269870009-RFWD2chr1175996824-0.0018162450.9981838
ENST00000409085ENST00000308769AAK1chr269870009-RFWD2chr1175996824-0.0027627390.9972372
ENST00000406297ENST00000367669AAK1chr269870009-RFWD2chr1175996824-0.0018162450.9981838
ENST00000406297ENST00000308769AAK1chr269870009-RFWD2chr1175996824-0.0027627390.9972372

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for AAK1-RFWD2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
AAK1chr269870009RFWD2chr117599682447787GRQQVTVDEVLAEVKLWSTNLDNSVA
AAK1chr269870009RFWD2chr117599682454087GRQQVTVDEVLAEVKLWSTNLDNSVA

Top

Potential FusionNeoAntigen Information of AAK1-RFWD2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AAK1-RFWD2_69870009_175996824.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:38TVDEVLAEV0.99490.6459514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:35TVDEVLAEV0.99390.6841514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:21TVDEVLAEV0.99370.7455514
AAK1-RFWD2chr269870009chr1175996824540HLA-B57:01EVLAEVKLW0.99210.9334817
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:67TVDEVLAEV0.99090.6618514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:24TVDEVLAEV0.99090.6618514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:30TVDEVLAEV0.99090.6618514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:20TVDEVLAEV0.99090.6659514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:29TVDEVLAEV0.99080.6594514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:60TVDEVLAEV0.99070.6774514
AAK1-RFWD2chr269870009chr1175996824540HLA-B18:01DEVLAEVKL0.99010.9237716
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:11TVDEVLAEV0.990.6754514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:22TVDEVLAEV0.9830.5369514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:04TVDEVLAEV0.98140.81514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:16TVDEVLAEV0.980.7432514
AAK1-RFWD2chr269870009chr1175996824540HLA-B58:01EVLAEVKLW0.97450.829817
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:27TVDEVLAEV0.97140.5907514
AAK1-RFWD2chr269870009chr1175996824540HLA-B08:01EVKLWSTNL0.97070.54811221
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:17TVDEVLAEV0.96920.6926514
AAK1-RFWD2chr269870009chr1175996824540HLA-B58:02EVLAEVKLW0.96740.8549817
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:13TVDEVLAEV0.96360.7664514
AAK1-RFWD2chr269870009chr1175996824540HLA-B57:03EVLAEVKLW0.82860.9177817
AAK1-RFWD2chr269870009chr1175996824540HLA-A32:13EVLAEVKLW0.81110.9492817
AAK1-RFWD2chr269870009chr1175996824540HLA-B44:03DEVLAEVKLW0.99910.923717
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:21VTVDEVLAEV0.99480.7284414
AAK1-RFWD2chr269870009chr1175996824540HLA-B57:01VDEVLAEVKLW10.9431617
AAK1-RFWD2chr269870009chr1175996824540HLA-C04:07TVDEVLAEV0.99990.9411514
AAK1-RFWD2chr269870009chr1175996824540HLA-C05:09TVDEVLAEV0.99990.9742514
AAK1-RFWD2chr269870009chr1175996824540HLA-C04:10TVDEVLAEV0.99990.9142514
AAK1-RFWD2chr269870009chr1175996824540HLA-C08:15TVDEVLAEV0.99960.9775514
AAK1-RFWD2chr269870009chr1175996824540HLA-C04:06TVDEVLAEV0.99790.9807514
AAK1-RFWD2chr269870009chr1175996824540HLA-C15:06TVDEVLAEV0.99770.9408514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:07TVDEVLAEV0.99130.6941514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:01TVDEVLAEV0.99090.6618514
AAK1-RFWD2chr269870009chr1175996824540HLA-C04:14TVDEVLAEV0.98570.9486514
AAK1-RFWD2chr269870009chr1175996824540HLA-C08:13TVDEVLAEV0.94690.9868514
AAK1-RFWD2chr269870009chr1175996824540HLA-C08:04TVDEVLAEV0.94690.9868514
AAK1-RFWD2chr269870009chr1175996824540HLA-C02:06TVDEVLAEV0.92770.9837514
AAK1-RFWD2chr269870009chr1175996824540HLA-C08:03TVDEVLAEV0.82760.9872514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:07VTVDEVLAEV0.99270.6882414
AAK1-RFWD2chr269870009chr1175996824540HLA-C08:15TVDEVLAEVKL10.9676516
AAK1-RFWD2chr269870009chr1175996824540HLA-C05:09TVDEVLAEVKL10.9173516
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:07TVDEVLAEVKL0.93440.599516
AAK1-RFWD2chr269870009chr1175996824540HLA-C18:01TVDEVLAEV0.99990.9346514
AAK1-RFWD2chr269870009chr1175996824540HLA-C05:01TVDEVLAEV0.99990.9742514
AAK1-RFWD2chr269870009chr1175996824540HLA-C04:03TVDEVLAEV0.99990.9517514
AAK1-RFWD2chr269870009chr1175996824540HLA-C04:01TVDEVLAEV0.99990.9411514
AAK1-RFWD2chr269870009chr1175996824540HLA-C08:02TVDEVLAEV0.99960.9775514
AAK1-RFWD2chr269870009chr1175996824540HLA-C01:03TVDEVLAEV0.99960.9506514
AAK1-RFWD2chr269870009chr1175996824540HLA-C15:02TVDEVLAEV0.99840.9418514
AAK1-RFWD2chr269870009chr1175996824540HLA-C15:05TVDEVLAEV0.99820.9587514
AAK1-RFWD2chr269870009chr1175996824540HLA-C04:04TVDEVLAEV0.99620.9804514
AAK1-RFWD2chr269870009chr1175996824540HLA-A68:02TVDEVLAEV0.99610.6854514
AAK1-RFWD2chr269870009chr1175996824540HLA-B18:04DEVLAEVKL0.99440.9339716
AAK1-RFWD2chr269870009chr1175996824540HLA-A69:01TVDEVLAEV0.99410.8695514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:14TVDEVLAEV0.99390.6772514
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:06TVDEVLAEV0.99370.7455514
AAK1-RFWD2chr269870009chr1175996824540HLA-B57:10EVLAEVKLW0.99210.9334817
AAK1-RFWD2chr269870009chr1175996824540HLA-B18:07DEVLAEVKL0.99190.8963716
AAK1-RFWD2chr269870009chr1175996824540HLA-B18:05DEVLAEVKL0.99010.9237716
AAK1-RFWD2chr269870009chr1175996824540HLA-B18:08DEVLAEVKL0.98810.8331716
AAK1-RFWD2chr269870009chr1175996824540HLA-B18:06DEVLAEVKL0.98720.9301716
AAK1-RFWD2chr269870009chr1175996824540HLA-A25:01EVLAEVKLW0.98710.8521817
AAK1-RFWD2chr269870009chr1175996824540HLA-B18:03DEVLAEVKL0.98520.9167716
AAK1-RFWD2chr269870009chr1175996824540HLA-B57:04EVLAEVKLW0.98370.6692817
AAK1-RFWD2chr269870009chr1175996824540HLA-A25:01EVKLWSTNL0.98190.90241221
AAK1-RFWD2chr269870009chr1175996824540HLA-B40:04DEVLAEVKL0.97350.6505716
AAK1-RFWD2chr269870009chr1175996824540HLA-A68:02EVKLWSTNL0.97310.62861221
AAK1-RFWD2chr269870009chr1175996824540HLA-B08:18EVKLWSTNL0.97070.54811221
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:03TVDEVLAEV0.96950.7454514
AAK1-RFWD2chr269870009chr1175996824540HLA-C03:06TVDEVLAEV0.9590.997514
AAK1-RFWD2chr269870009chr1175996824540HLA-B15:13EVLAEVKLW0.94690.6001817
AAK1-RFWD2chr269870009chr1175996824540HLA-C17:01TVDEVLAEV0.94290.983514
AAK1-RFWD2chr269870009chr1175996824540HLA-B57:02EVLAEVKLW0.90860.8874817
AAK1-RFWD2chr269870009chr1175996824540HLA-B51:05TVDEVLAEV0.83720.5989514
AAK1-RFWD2chr269870009chr1175996824540HLA-C08:01TVDEVLAEV0.82760.9872514
AAK1-RFWD2chr269870009chr1175996824540HLA-B18:11DEVLAEVKL0.80020.9093716
AAK1-RFWD2chr269870009chr1175996824540HLA-B08:12EVKLWSTNL0.64630.74521221
AAK1-RFWD2chr269870009chr1175996824540HLA-C07:04TVDEVLAEV0.31640.906514
AAK1-RFWD2chr269870009chr1175996824540HLA-B39:31DEVLAEVKL0.13360.9399716
AAK1-RFWD2chr269870009chr1175996824540HLA-B07:13TVDEVLAEV0.10270.8818514
AAK1-RFWD2chr269870009chr1175996824540HLA-B44:13DEVLAEVKLW0.99910.923717
AAK1-RFWD2chr269870009chr1175996824540HLA-B44:07DEVLAEVKLW0.99910.923717
AAK1-RFWD2chr269870009chr1175996824540HLA-B44:26DEVLAEVKLW0.99910.923717
AAK1-RFWD2chr269870009chr1175996824540HLA-A68:02VTVDEVLAEV0.99720.6719414
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:14VTVDEVLAEV0.99490.6739414
AAK1-RFWD2chr269870009chr1175996824540HLA-A02:06VTVDEVLAEV0.99480.7284414
AAK1-RFWD2chr269870009chr1175996824540HLA-B40:04AEVKLWSTNL0.99450.71751121
AAK1-RFWD2chr269870009chr1175996824540HLA-A69:01VTVDEVLAEV0.99450.8694414
AAK1-RFWD2chr269870009chr1175996824540HLA-C08:02TVDEVLAEVKL10.9676516
AAK1-RFWD2chr269870009chr1175996824540HLA-B57:10VDEVLAEVKLW10.9431617
AAK1-RFWD2chr269870009chr1175996824540HLA-C05:01TVDEVLAEVKL10.9173516
AAK1-RFWD2chr269870009chr1175996824540HLA-C04:03TVDEVLAEVKL10.8292516

Top

Potential FusionNeoAntigen Information of AAK1-RFWD2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AAK1-RFWD2_69870009_175996824.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AAK1-RFWD2chr269870009chr1175996824540DRB1-0301GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0301RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0310GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0310RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0313GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0313RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0315GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0315RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0318GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0318RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0320GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0320RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0322GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0322RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0326GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0326RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0328GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0328RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0330GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0330RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0332GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0332RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0334GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0334RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0336GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0336RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0342GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0342RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0344GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0344RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0346GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0346RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0348GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0348RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0350GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0350RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0352GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0352RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0354GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0354RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0422GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0422RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-0467GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-0467RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-1394GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-1394RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-1457LAEVKLWSTNLDNSV1025
AAK1-RFWD2chr269870009chr1175996824540DRB1-1457VLAEVKLWSTNLDNS924
AAK1-RFWD2chr269870009chr1175996824540DRB1-1457AEVKLWSTNLDNSVA1126
AAK1-RFWD2chr269870009chr1175996824540DRB1-1457EVLAEVKLWSTNLDN823
AAK1-RFWD2chr269870009chr1175996824540DRB1-1476GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-1476RQQVTVDEVLAEVKL116
AAK1-RFWD2chr269870009chr1175996824540DRB1-1479GRQQVTVDEVLAEVK015
AAK1-RFWD2chr269870009chr1175996824540DRB1-1479RQQVTVDEVLAEVKL116

Top

Fusion breakpoint peptide structures of AAK1-RFWD2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
9843VDEVLAEVKLWSTNAAK1RFWD2chr269870009chr1175996824540

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of AAK1-RFWD2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN9843VDEVLAEVKLWSTN-6.81784-6.93724
HLA-B14:023BVN9843VDEVLAEVKLWSTN-5.72956-6.77086
HLA-B52:013W399843VDEVLAEVKLWSTN-7.39683-7.51623
HLA-B52:013W399843VDEVLAEVKLWSTN-6.35068-7.39198
HLA-A11:014UQ29843VDEVLAEVKLWSTN-2.93775-3.05715
HLA-A24:025HGA9843VDEVLAEVKLWSTN-8.28894-8.40834
HLA-A24:025HGA9843VDEVLAEVKLWSTN-6.60463-7.64593
HLA-B44:053DX89843VDEVLAEVKLWSTN-6.05305-6.17245
HLA-B44:053DX89843VDEVLAEVKLWSTN-2.83839-3.87969
HLA-A02:016TDR9843VDEVLAEVKLWSTN-7.33893-7.45833

Top

Vaccine Design for the FusionNeoAntigens of AAK1-RFWD2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
AAK1-RFWD2chr269870009chr11759968241121AEVKLWSTNLCGGAAGTGAAGCTGTGGTCTACCAATCTAG
AAK1-RFWD2chr269870009chr11759968241221EVKLWSTNLAAGTGAAGCTGTGGTCTACCAATCTAG
AAK1-RFWD2chr269870009chr1175996824414VTVDEVLAEVTCACAGTGGACGAGGTGTTGGCGGAAGTGA
AAK1-RFWD2chr269870009chr1175996824514TVDEVLAEVCAGTGGACGAGGTGTTGGCGGAAGTGA
AAK1-RFWD2chr269870009chr1175996824516TVDEVLAEVKLCAGTGGACGAGGTGTTGGCGGAAGTGAAGCTGT
AAK1-RFWD2chr269870009chr1175996824617VDEVLAEVKLWTGGACGAGGTGTTGGCGGAAGTGAAGCTGTGGT
AAK1-RFWD2chr269870009chr1175996824716DEVLAEVKLACGAGGTGTTGGCGGAAGTGAAGCTGT
AAK1-RFWD2chr269870009chr1175996824717DEVLAEVKLWACGAGGTGTTGGCGGAAGTGAAGCTGTGGT
AAK1-RFWD2chr269870009chr1175996824817EVLAEVKLWAGGTGTTGGCGGAAGTGAAGCTGTGGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
AAK1-RFWD2chr269870009chr1175996824015GRQQVTVDEVLAEVKGGCGACAGCAGGTCACAGTGGACGAGGTGTTGGCGGAAGTGAAGC
AAK1-RFWD2chr269870009chr1175996824116RQQVTVDEVLAEVKLGACAGCAGGTCACAGTGGACGAGGTGTTGGCGGAAGTGAAGCTGT
AAK1-RFWD2chr269870009chr11759968241025LAEVKLWSTNLDNSVTGGCGGAAGTGAAGCTGTGGTCTACCAATCTAGACAACTCAGTGG
AAK1-RFWD2chr269870009chr11759968241126AEVKLWSTNLDNSVACGGAAGTGAAGCTGTGGTCTACCAATCTAGACAACTCAGTGGCAA
AAK1-RFWD2chr269870009chr1175996824823EVLAEVKLWSTNLDNAGGTGTTGGCGGAAGTGAAGCTGTGGTCTACCAATCTAGACAACT
AAK1-RFWD2chr269870009chr1175996824924VLAEVKLWSTNLDNSTGTTGGCGGAAGTGAAGCTGTGGTCTACCAATCTAGACAACTCAG

Top

Information of the samples that have these potential fusion neoantigens of AAK1-RFWD2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADAAK1-RFWD2chr269870009ENST00000406297chr1175996824ENST00000308769TCGA-BR-A452

Top

Potential target of CAR-T therapy development for AAK1-RFWD2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to AAK1-RFWD2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to AAK1-RFWD2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource